Cite
HARVARD Citation
Xu, Z. et al. (2021). Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC). Thoracic cancer. 12 (17), pp. 2360-2368. [Online].